Research programme: Psorospermin analogues - CyleneAlternative Names: CX-1338; Psorospermin analogues research programme - Cylene
Latest Information Update: 24 Dec 2013
At a glance
- Originator Cylene Pharmaceuticals
- Class Xanthones
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jan 2013 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 31 Oct 2003 Preclinical trials in Cancer in USA (unspecified route)